R. Salem

Hepatology · 2006–2022

A researcher in the Science corpus: 9 papers; trusts 1 researcher and is trusted by 0 researchers here, as inferred from the citation graph.

Subfields

• Hepatology — 87 citations into it

Whom R. Salem trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

1. Jordi Bruix1 , 2
2. J. Llovet
3. M. Sherman
4. Miguel A. Hern'an

Who trusts R. Salem overall

1. L. Kulik
2. Jorge Marrero
3. J. Llovet
4. Claude B. Sirlin

Papers from R. Salem's perspective

Ordered by how strongly the researchers R. Salem trusts endorse each paper. Same corpus, a different order for every researcher.

1. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. (The Lancet Oncology)
2. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. (The Lancet)
3. Sorafenib in advanced hepatocellular carcinoma. (New England Journal of Medicine)
4. Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma (Gastroenterology)
5. Radioembolization with 90Yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. Part 1: Technical and methodologic considerations. (Journal of Vascular and Interventional Radiology)
6. The Barcelona approach: Diagnosis, staging, and treatment of hepatocellular carcinoma (Liver transplantation)
7. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. (The Lancet Oncology)
8. Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men.
9. Management of hepatocellular carcinoma: An update (Hepatology)
10. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. (Journal of Clinical Oncology)

Their papers

• Hepatocellular carcinoma (2022) — 944 citations
• Y90 Radioembolization Significantly Prolongs Time to Progression Compared With Chemoembolization in Patients With Hepatocellular Carcinoma (2016) — 595 citations
• Image-guided tumor ablation: standardization of terminology and reporting criteria--a 10-year update. (2014) — 921 citations
• Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. (2010) — 1,037 citations
• Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma (2010) — 667 citations
• NCCN clinical practice guidelines in oncology: hepatobiliary cancers. (2009) — 2,224 citations
• A Comparative Analysis of Transarterial Downstaging for Hepatocellular Carcinoma: Chemoembolization Versus Radioembolization (2009) — 596 citations
• Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the radioembolization brachytherapy oncology consortium. (2007) — 702 citations
• Radioembolization with 90Yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. Part 1: Technical and methodologic considerations. (2006) — 676 citations